A detailed history of Price T Rowe Associates Inc transactions in Xencor Inc stock. As of the latest transaction made, Price T Rowe Associates Inc holds 3,929,062 shares of XNCR stock, worth $94.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,929,062
Previous 3,962,403 0.84%
Holding current value
$94.8 Million
Previous $75 Million 5.34%
% of portfolio
0.01%
Previous 0.01%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$15.7 - $21.65 $523,453 - $721,832
-33,341 Reduced 0.84%
3,929,062 $79 Million
Q2 2024

Aug 14, 2024

BUY
$18.21 - $24.5 $2.6 Million - $3.5 Million
142,747 Added 3.74%
3,962,403 $75 Million
Q1 2024

May 15, 2024

BUY
$18.65 - $26.52 $6.26 Million - $8.91 Million
335,881 Added 9.64%
3,819,656 $84.5 Million
Q4 2023

Feb 14, 2024

BUY
$16.53 - $21.42 $4.94 Million - $6.4 Million
298,841 Added 9.38%
3,483,775 $74 Million
Q3 2023

Nov 14, 2023

BUY
$20.08 - $25.39 $529,268 - $669,229
26,358 Added 0.83%
3,184,934 $64.2 Million
Q2 2023

Aug 14, 2023

SELL
$24.77 - $29.9 $3.23 Million - $3.9 Million
-130,313 Reduced 3.96%
3,158,576 $78.9 Million
Q1 2023

May 15, 2023

BUY
$25.95 - $36.95 $1.82 Million - $2.59 Million
70,128 Added 2.18%
3,288,889 $91.7 Million
Q4 2022

Feb 14, 2023

BUY
$24.79 - $30.86 $226,828 - $282,369
9,150 Added 0.29%
3,218,761 $83.8 Million
Q3 2022

Nov 14, 2022

SELL
$24.62 - $32.44 $83.4 Million - $110 Million
-3,389,460 Reduced 51.36%
3,209,611 $83.4 Million
Q2 2022

Aug 15, 2022

BUY
$19.74 - $29.01 $14.7 Million - $21.6 Million
744,569 Added 12.72%
6,599,071 $181 Million
Q1 2022

May 16, 2022

SELL
$26.68 - $41.63 $1.45 Million - $2.26 Million
-54,181 Reduced 0.92%
5,854,502 $156 Million
Q4 2021

Feb 14, 2022

SELL
$33.67 - $43.44 $790,908 - $1.02 Million
-23,490 Reduced 0.4%
5,908,683 $237 Million
Q3 2021

Nov 15, 2021

BUY
$30.65 - $35.68 $2.09 Million - $2.44 Million
68,264 Added 1.16%
5,932,173 $194 Million
Q2 2021

Aug 16, 2021

BUY
$34.33 - $44.68 $5.64 Million - $7.34 Million
164,248 Added 2.88%
5,863,909 $202 Million
Q1 2021

May 17, 2021

BUY
$40.81 - $53.88 $379,737 - $501,353
9,305 Added 0.16%
5,699,661 $245 Million
Q4 2020

Feb 16, 2021

BUY
$36.63 - $47.63 $208 Million - $271 Million
5,690,356 New
5,690,356 $248 Million

Others Institutions Holding XNCR

About Xencor Inc


  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.44B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.